Impacts of the 2019 pandemic of severe acute respiratory syndrome–coronavirus 2 on the quality of life of patients with inflammatory rheumatic diseases
{"title":"Impacts of the 2019 pandemic of severe acute respiratory syndrome–coronavirus 2 on the quality of life of patients with inflammatory rheumatic diseases","authors":"Domen Lah, I. Holc","doi":"10.18690/actabiomed.248","DOIUrl":null,"url":null,"abstract":"Purpose: The aim of this study was to assess the impact of the SARS-CoV-2 pandemic and protective measures on the QoL of patients with inflammatory rheumatic diseases (IRDs) who received treatment at the Department of Rheumatology at the University Medical Centre Maribor (UCM-MB). \nMethods: A questionnaire was sent to IRD patients who visited a rheumatology outpatient clinic or were contacted by phone or virtually at least once between February 1, 2020 and May 30, 2021. The questionnaires were included if returned to UCM-MB by January 1, 2022 and were completed correctly and in full. \nResults: Of the 125 patients who met the inclusion criteria, 57 (45.6%) had no cancelled rheumatology appointments, 52 (41.6%) had one, 15 (12.0%) had two, and one patient (0.8%) had three. The most preferred mode of communication was in-person meetings with a rheumatologist (89%) and the least was a video call (1%). Only 2% of patients had problems obtaining medication during the pandemic, but none reported consequences with disease status. More than half (58%) of patients agreed with the restrictions during the pandemic and 5% stated the restrictions should be terminated. Most (70%) patients were vaccinated against SARS-CoV-2 and 21% reported SARS-CoV-2 infection. The mean disease activity score (DAS-28) was 3.100 ± 1.292 (rheumatoid arthritis, 3.252 ± 1.209; psoriatic arthritis, 2.927 ± 1.376; p = 0.274; t = 1.101). \nConclusion: The pandemic and associated protective measures had deleterious effects on the QoL of IRD patients.","PeriodicalId":186880,"journal":{"name":"Acta Medico-Biotechnica","volume":"25 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Medico-Biotechnica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18690/actabiomed.248","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The aim of this study was to assess the impact of the SARS-CoV-2 pandemic and protective measures on the QoL of patients with inflammatory rheumatic diseases (IRDs) who received treatment at the Department of Rheumatology at the University Medical Centre Maribor (UCM-MB).
Methods: A questionnaire was sent to IRD patients who visited a rheumatology outpatient clinic or were contacted by phone or virtually at least once between February 1, 2020 and May 30, 2021. The questionnaires were included if returned to UCM-MB by January 1, 2022 and were completed correctly and in full.
Results: Of the 125 patients who met the inclusion criteria, 57 (45.6%) had no cancelled rheumatology appointments, 52 (41.6%) had one, 15 (12.0%) had two, and one patient (0.8%) had three. The most preferred mode of communication was in-person meetings with a rheumatologist (89%) and the least was a video call (1%). Only 2% of patients had problems obtaining medication during the pandemic, but none reported consequences with disease status. More than half (58%) of patients agreed with the restrictions during the pandemic and 5% stated the restrictions should be terminated. Most (70%) patients were vaccinated against SARS-CoV-2 and 21% reported SARS-CoV-2 infection. The mean disease activity score (DAS-28) was 3.100 ± 1.292 (rheumatoid arthritis, 3.252 ± 1.209; psoriatic arthritis, 2.927 ± 1.376; p = 0.274; t = 1.101).
Conclusion: The pandemic and associated protective measures had deleterious effects on the QoL of IRD patients.